BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 23, 2025
Home » Authors » Jim Stommen

Articles by Jim Stommen

The MDD Interview: Size, geographic fit are key in hospitals consolidation

Aug. 30, 2013
By Jim Stommen

The MDD Interview: Modulating risk seen as key in hospitals' merger mania

Aug. 22, 2013
By Jim Stommen

The MDD Interview: Browning: Regulating electronic interfaces is can of worms for FDA

Aug. 15, 2013
By Jim Stommen

Deals roundup: Medtronic says Cardiocom advances its push on services

Aug. 13, 2013
By Jim Stommen

The MDD Interview: Change is imminent as FDA, industry forge new relationship

Aug. 8, 2013
By Jim Stommen

The MDD Interview: Ongoing mentoring builds upon lessons of initial training for vets

Aug. 1, 2013
By Jim Stommen

The MDD Interview: Returning veterans are focus of 'jobs in med-tech' program

July 25, 2013
By Jim Stommen

The MDD Interview: Schain: Market opportunity for CampusMD is almost limitless

July 18, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. Schain now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: CampusMD uses telemedicine to help fill college health gaps

July 11, 2013
By Jim Stommen
Devin Schain is the co-founder and CEO of CampusMD (Bethesda, Maryland), a provider of telemedicine-based services. CampusMD is underwritten by HealthNation, a nationwide telehealth service with an independent network of licensed physicians across the U.S., providing participating students with 24/7 access to U.S.-based, licensed physicians via telephone, online video and secure e-mail. Schain has founded and led several companies in the education space, launching his first as an undergraduate at the University of Pennsylvania. He now heads CampusDirect, a portfolio company that includes CampusMD among its businesses.
Read More

The MDD Interview: Presence of other players doesn't diminish opportunities in epilepsy

July 3, 2013
By Jim Stommen
Previous 1 2 3 4 5 6 7 8 9 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing